Charles Schwab
CASI

Charles Schwab’s CASI Pharmaceuticals CASI Stock Holding History

Charles Schwab’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,406
Closed -$44K – 3556
2022
Q1 		$44K Hold
5,406
– – ﹤0.01% 3546
2021
Q4 		$44K Hold
5,406
– – ﹤0.01% 3523
2021
Q3 		$65K Sell
5,406
-35,123
-87% -$475K ﹤0.01% 3420
2021
Q2 		$629K Sell
40,529
-10,144
-20% -$171K ﹤0.01% 3091
2021
Q1 		$1.22M Buy
50,673
+2,662
+6% +$74.8K ﹤0.01% 2790
2020
Q4 		$1.42M Buy
48,011
+822
+2% +$17.9K ﹤0.01% 2683
2020
Q3 		$722K Buy
47,189
+13,709
+41% +$258K ﹤0.01% 2767
2020
Q2 		$837K Buy
33,480
+2,991
+10% +$65K ﹤0.01% 2677
2020
Q1 		$622K Buy
30,489
+435
+1% +$10.4K ﹤0.01% 2640
2019
Q4 		$929K Buy
30,054
+2,697
+10% +$87.5K ﹤0.01% 2621
2019
Q3 		$914K Sell
27,357
-3,968
-13% -$127K ﹤0.01% 2602
2019
Q2 		$1M Buy
31,325
+5,950
+23% +$190K ﹤0.01% 2572
2019
Q1 		$729K Sell
25,375
-1,965
-7% -$68.5K ﹤0.01% 2645
2018
Q4 		$1.1M Sell
27,340
-331
-1% -$12.5K ﹤0.01% 2512
2018
Q3 		$1.29M Buy
27,671
+17,275
+166% +$1.21M ﹤0.01% 2543
2018
Q2 		$856K Buy
+10,396
New +$702K ﹤0.01% 2628

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab's CASI Position: Q2 2022 in Review

Charles Schwab sold out of CASI Pharmaceuticals (CASI) in Q2 2022, closing a stake of 5,406 shares — an estimated $44K sold.

Charles Schwab first reported a position in CASI in Q2 2018 and held it in 16 quarters. The position peaked at $1.42M in Q4 2020. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2022.

  • Charles Schwab reported no remaining CASI Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 5,406 CASI Pharmaceuticals shares in Q2 2022, an estimated $44K.
  • Charles Schwab first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 16 quarters.
  • Charles Schwab's CASI Pharmaceuticals position peaked at $1.42M in Q4 2020.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.